- Conditions
- Cryopyrin-Associated Periodic Syndrome
- Interventions
- ATI-450
- Drug
- Lead sponsor
- Aclaris Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 2
- States / cities
- San Diego, California • San Francisco, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 841–864
of 1,850
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Mucopolysaccharidosis Type I (MPS I), Mucopolysaccharidosis Type II (MPS II), Mucopolysaccharidosis Type III (MPS III), Mucopolysaccharidosis Type VI (MPS VI), Krabbe Disease
- Interventions
- Not listed
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 1 Day to 18 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Minneapolis, Minnesota • Buffalo, New York
- Conditions
- Normal Volunteers, Atopic Dermatitis (AD), Atopic Eczema, Atopic Eczema/Dermatitis (Non-Specific)
- Interventions
- ATTO-3712, Placebo
- Drug
- Lead sponsor
- Attovia Therapeutics Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 9
- States / cities
- Encinitas, California • Fountain Valley, California • Huntington Beach, California + 6 more
- Conditions
- Mucopolysaccharidosis Type IIIA
- Interventions
- DNL126
- Drug
- Lead sponsor
- Denali Therapeutics Inc.
- Industry
- Eligibility
- 0 Years to 18 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 4
- States / cities
- Oakland, California • Iowa City, Iowa • Chapel Hill, North Carolina + 1 more
- Conditions
- Skin Laxity, Wrinkle, Skin Condition
- Interventions
- Profound Matrix
- Device
- Lead sponsor
- Candela Corporation
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2028
- U.S. locations
- 4
- States / cities
- Jacksonville, Florida • Marlborough, Massachusetts • Fayetteville, North Carolina + 1 more
- Conditions
- Atopic Dermatitis
- Interventions
- 1.1% w/w AMTX-100 CF-part1, Placebo, 1.1% w/w AMTX-100 CF3-part2
- Drug
- Lead sponsor
- Amytrx Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 11
- States / cities
- Cerritos, California • Encino, California • Long Beach, California + 8 more
- Conditions
- Neurofibromatosis 1
- Interventions
- Deoxycholic Acid, Polidocanol, 1064nm Nd:YAG laser, 755nm Alexandrite Laser
- Drug · Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
- Interventions
- recombinant interleukin-12
- Biological
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Rhytids, Skin Laxity
- Interventions
- 2,910 nm mid-infrared erbium-doped fluoride fiber glass laser (UltraClear, Acclaro Medical)
- Device
- Lead sponsor
- FA Corporation
- Industry
- Eligibility
- 45 Years to 85 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Edina, Minnesota
- Conditions
- Alport Syndrome, Kidney Disease
- Interventions
- Not listed
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- Up to 18 Years · Male only
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Dermatitis, Atopic, Pruritus
- Interventions
- ASN008, ASN008 Matching Vehicle
- Drug · Other
- Lead sponsor
- Formation Bio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 27
- States / cities
- Scottsdale, Arizona • Hot Springs, Arkansas • Beverly Hills, California + 23 more
- Conditions
- Primary Immunodeficiency, DOCK8, Virus Susceptibility
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 2 Years to 85 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2009
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Skin Lesion, Skin Abnormalities, Sebaceous Hyperplasia
- Interventions
- CellFX System, Intralesional Electrodesiccation
- Device
- Lead sponsor
- Pulse Biosciences, Inc.
- Industry
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • Edina, Minnesota • Charlotte, North Carolina + 2 more
- Conditions
- Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Diffuse Large Cell Lymphoma, Childhood Grade III Lymphomatoid Granulomatosis, Childhood Immunoblastic Large Cell Lymphoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Liver Cancer, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway Glioma, Recurrent Colon Cancer, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Melanoma, Recurrent Nasopharyngeal Cancer, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Recurrent/Refractory Childhood Hodgkin Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- irinotecan hydrochloride, oxaliplatin
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- Arcadia, California
- Conditions
- Ichthyosis
- Interventions
- Observation
- Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- Up to 3 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Atopic Dermatitis
- Interventions
- Text message to cell phone
- Procedure
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 2
- States / cities
- Chicago, Illinois
- Conditions
- Psoriasis, Atopic Dermatitis
- Interventions
- CT-100-004-A, CT-100-004-B
- Device
- Lead sponsor
- Click Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hereditary Angioedema
- Interventions
- NTLA-2002, Normal Saline IV Administration
- Biological
- Lead sponsor
- Intellia Therapeutics
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 14
- States / cities
- Scottsdale, Arizona • San Diego, California • Santa Monica, California + 11 more
- Conditions
- Sanfilippo Syndrome Type C, Mucopolysaccharidosis (MPS) IIIC
- Interventions
- Not listed
- Lead sponsor
- Phoenix Nest
- Industry
- Eligibility
- 1 Year to 25 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Cancer
- Interventions
- aprepitant, dexamethasone, ondansetron, placebo
- Drug
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Atopic Dermatitis
- Interventions
- Lebrikizumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 254 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 85
- States / cities
- Birmingham, Alabama • Hot Springs, Arkansas • North Little Rock, Arkansas + 67 more
- Conditions
- Cancer
- Interventions
- cytomegalovirus IE-1-specific cytotoxic T lymphocytes, cytomegalovirus pp65-specific cytotoxic T lymphocytes, therapeutic allogeneic lymphocytes, polymerase chain reaction, flow cytometry, immunological diagnostic method, laboratory biomarker analysis
- Biological · Genetic · Other
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Adrenoleukodystrophy, Metachromatic Leukodystrophy, Globoid Cell Leukodystrophy, Tay Sachs Disease, Sandhoffs Disease, Wolman Disease, I-Cell Disease, Sanfilippo Syndrome, GM1 Gangliosidosis
- Interventions
- Clofarabine, Total body Irradiation, Melphalan, Hematopoietic Stem Cell Transplantation, Alemtuzumab, mycophenylate mofetil, Cyclosporine A, Hydroxyurea
- Drug · Procedure · Biological + 1 more
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 70 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Hypohidrotic Ectodermal Dysplasia, X-Linked Hypohidrotic Ectodermal Dysplasia
- Interventions
- Not listed
- Lead sponsor
- Edimer Pharmaceuticals
- Industry
- Eligibility
- Not listed
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 1
- States / cities
- Cambridge, Massachusetts